9 results match your criteria: "University of Pennsylvania and VA Medical Center[Affiliation]"

Objective: Racial and ethnic disparities in rheumatoid arthritis (RA) outcomes are well recognized. However, whether disparities in RA treatment selection and outcomes differ by urban versus rural residence, independent of race, have not been studied. Our objective was to evaluate whether biologic disease-modifying antirheumatic drug (bDMARD) initiation after methotrexate administration differs by rural versus urban residence among veterans with RA.

View Article and Find Full Text PDF

Objective: MUC5B and TOLLIP single nucleotide polymorphisms (SNPs) and cigarette smoking were associated with rheumatoid arthritis-interstitial lung disease (RA-ILD) in a predominantly Northern European population. We evaluated whether RA-ILD is associated with these genetic variants and HLA-DRB1 shared epitope (SE) alleles in a large RA cohort stratified by race and smoking history.

Methods: HLA-DRB1 SE alleles and MUC5B rs35705950 and TOLLIP rs5743890 SNPs were genotyped in U.

View Article and Find Full Text PDF

Objective: To determine the acceptable level of positive predictive value (PPV) and negative predictive value (NPV) for classification criteria for gout, given the type of study.

Methods: We conducted an international web-based survey with 91 general practitioners and rheumatologists experienced in gout. Conjoint analysis was used as the framework for designing and analyzing pairs of 2 profiles, each describing a study type, a PPV, and an NPV.

View Article and Find Full Text PDF

Objective: To determine which clinical, laboratory, and imaging features most accurately distinguished gout from non-gout.

Methods: We performed a cross-sectional study of consecutive rheumatology clinic patients with ≥1 swollen joint or subcutaneous tophus. Gout was defined by synovial fluid or tophus aspirate microscopy by certified examiners in all patients.

View Article and Find Full Text PDF

Some suggestions for reviewers and for authors to know what reviewers may be looking for.

J Clin Rheumatol

August 2014

From the *University of Pennsylvania and VA Medical Center, Philadelphia, PA; JCR: Journal of Clinical Rheumatology; and †Philadelphia Veterans Medical Center, and Division of Rheumatology, University of Pennsylvania, PA.

View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to evaluate the effectiveness and safety of febuxostat compared to allopurinol and placebo in treating hyperuricemia and gout among over 1,000 participants, including those with renal issues.
  • Participants were randomly assigned to receive different doses of febuxostat, allopurinol, or placebo for 28 weeks, with results showing that febuxostat significantly reduced serum urate levels compared to allopurinol and placebo.
  • Despite general safety across groups, febuxostat was associated with more incidences of gout flares and some specific side effects like diarrhea and dizziness at higher doses, yet it proved to be more effective overall in managing serum urate levels.
View Article and Find Full Text PDF

Amiloride is a prototypic inhibitor of epithelial sodium channels. Rapid progress has been made in our understanding of the structure of the sodium channel and related cation-selective channels. This work, coupled with experiments examining how selected sodium channel mutations affect amiloride binding, provides critical clues towards defining sites within the channel that bind amiloride.

View Article and Find Full Text PDF